Welcome to our dedicated page for Abbott Labs SEC filings (Ticker: ABT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page provides access to U.S. Securities and Exchange Commission (SEC) filings for Abbott Laboratories (NYSE: ABT), an Illinois-incorporated healthcare company whose common shares are listed on the New York Stock Exchange. Through these filings, investors can review official disclosures on Abbott’s operations, governance, financial reporting practices and material corporate events.
Abbott’s SEC filings include periodic reports and current reports on Form 8-K. Recent 8-K filings describe matters such as the entry into an Agreement and Plan of Merger with Exact Sciences Corporation, under which a wholly owned Abbott subsidiary will merge with Exact Sciences, with Exact Sciences surviving as a direct, wholly owned subsidiary of Abbott subject to customary closing conditions. Another 8-K details a notice of a blackout period for certain employee benefit plans due to administrative changes, including recordkeeper, trustee and custodian transitions, and outlines related trading restrictions for directors and executive officers. Additional 8-K disclosures cover corporate governance updates, such as amendments to Abbott’s by-laws to change the size of the board of directors and the appointment of a new director, as well as announcements of quarterly financial results and the company’s use of non-GAAP financial measures.
On Stock Titan, each new Abbott filing from the SEC’s EDGAR system can be viewed alongside AI-powered summaries that explain key points in clear language. These summaries help readers quickly understand topics like merger terms, benefit plan blackout periods, board changes, or how management presents adjusted financial metrics, without having to parse every technical detail. Users can also review exhibits referenced in the filings, such as merger agreements, notices to directors and officers, and amended by-laws, to see the underlying legal documents.
For those tracking insider-related information, governance changes or major transactions, Abbott’s SEC filings offer an authoritative record of the company’s regulatory disclosures, while AI-generated insights on this page aim to make those documents more accessible and easier to interpret.
Abbott Laboratories is asking shareholders to vote on five items at its 2026 Annual Meeting, including electing 12 directors, ratifying Ernst & Young as auditors, approving executive pay on an advisory basis, and adopting new 2026 incentive and non‑U.S. employee stock purchase plans.
The proxy highlights strong long-term performance, with 2025 total shareholder return of 13% versus a 7% peer median, and three‑ and five‑year TSR of 21% and 25%, both above peers. Abbott returned $5 billion to shareholders in 2025 and raised its dividend by 6.8%, its 54th consecutive annual increase.
The board stresses governance, noting that 11 of 12 nominees are independent, all directors are elected annually by majority vote, and committees are fully independent. The company also emphasizes sustainability and human capital goals, including a 2030 plan to expand access to healthcare, cut emissions, and build a diverse, future-ready workforce.
Abbott Laboratories completed a major debt financing, issuing $20 billion of senior notes in multiple tranches maturing between 2029 and 2066, including fixed-rate coupons from 3.700% to 5.600% and a floating-rate 2029 series.
Abbott plans to use the net proceeds, along with cash and possible additional borrowings, to fund the acquisition of Exact Sciences Corporation, repay Exact Sciences’ debt, cover related fees and expenses, and for general corporate purposes such as debt repayment. If the Exact Sciences acquisition is not completed by a deadline tied to the merger agreement’s End Date, or Abbott abandons the deal, Abbott must redeem all outstanding notes at 101% of principal plus accrued interest under a special mandatory redemption feature.
Abbott Laboratories senior vice president Eric Shroff reported two stock transactions involving Abbott common shares. On March 2, 2026, he completed an open-market sale of 709 shares at a price of $115.58 per share, leaving him with 39,164 directly held shares afterward.
On February 27, 2026, he disposed of 1,384 shares at $116.26 per share to cover tax withholding obligations, a non-market transaction typically linked to equity compensation. Both holdings are reported as direct ownership of common shares without par value.
Abbott Laboratories executive Christopher J. Scoggins reported a tax-related share disposition. On February 27, 2026, he had 4,997 common shares withheld at $116.26 per share in a tax-withholding disposition, classified under code F as payment of tax liability by delivering securities.
After this non-open-market transaction, Scoggins’ directly owned holdings in Abbott Laboratories common shares were reported as 77,126 shares.
Abbott Laboratories executive Daniel Gesua Sive Salvadori, EVP and Group President, reported two share transactions. On March 2, 2026, he executed an open-market sale of 885 common shares at $115.58 per share. On February 27, 2026, he disposed of 6,615 shares at $116.26 per share to satisfy tax-withholding obligations. Following these transactions, he directly holds 146,377 Abbott common shares.
Abbott Laboratories executive Louis H. Morrone reported selling 1,144 common shares in an open‑market transaction at $115.58 per share on March 2, 2026. After this sale, his directly held stake was 76,843 common shares.
On February 27, 2026, 4,040 common shares were disposed of at $116.26 per share to cover tax withholding obligations rather than as an open‑market sale. The filing also notes 12 common shares held indirectly through a Profit Sharing Trust as of February 27, 2026.
ABBOTT LABORATORIES Executive Vice President Mary K. Moreland reported insider share transactions. On March 2, 2026, she completed an open-market sale of 613 common shares at $115.58 per share. On February 27, 2026, 4,630 common shares were disposed of at $116.26 per share to cover tax liabilities by delivering shares.
After these transactions, her directly held common shares totaled 104,291. In addition, 11,845 common shares were held indirectly through a Profit Sharing Trust, with that trust balance reported as of February 27, 2026.
Abbott Laboratories vice president and controller John A. McCoy Jr. reported multiple transactions in Abbott common shares. On March 2, 2026, he completed an open-market sale of 585 shares at $115.58 per share. On February 27, 2026, he disposed of 1,142 shares at $116.26 per share to cover tax obligations by delivering shares rather than cash. After these transactions, he held 24,628 common shares directly. A separate indirect holding of 58 shares was reported in a Profit Sharing Trust, with the balance noted as of February 27, 2026.
Abbott Laboratories Chairman and CEO Robert B. Ford reported a tax-related share disposition. On February 27, 2026, he disposed of 30,308 common shares at $116.26 per share through a tax-withholding transaction, a method used to satisfy tax obligations rather than an open-market sale.
After this transaction, Ford held 306,461 common shares directly. In addition, 216,203 common shares were held indirectly through the Ford Family Trust, where he serves as co-trustee, reflecting an additional layer of beneficial ownership separate from his direct holdings.